Rubius Therapeutics, Inc. As previously disclosed by the Company's Current Report on Form 8-K filed with the Commission on February 6, 2023 (the “February 8-K”), Dannielle Appelhans' employment as the Company's Chief Executive Officer and President was expected to terminate no later than January 31, 2023, but in light of the Company's continued review of strategic alternatives, Ms. Appelhans agreed to continue to serve as the Company's Chief Executive Officer and President until no later than March 3, 2023 (the “Extension of Services Arrangement”). Pursuant to the Extension of Services Arrangement, Ms. Appelhans' position as Chief Executive Officer and President of the Company terminated on March 3, 2023. Ms. Appelhans' termination was not due to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.